

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


PATENT
Attorney Docket No.: 016303-007510US

Assistant Commissioner for Patents
Washington, D.C. 20231

On 9-8-99

TOWNSEND and TOWNSEND and CREW LLP

By: Xanda Shaffer



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

JOSHI *et al.*

Application No.: 09/295,925

Filed: April 21, 1999

For: COMBINATION THERAPY
USING NUCLEIC ACIDS AND RADIO
THERAPY

Examiner: Not yet assigned

Art Unit: 1636

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Box SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notice to File Missing Parts of Application mailed May 20, 1999, Applicants submit herewith the required paper copy and computer readable copy of the Sequence Listing. Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

IN THE SPECIFICATION:

On page 8, line 2, insert --(LIFDRHPIAALLCYP = SEQ ID NO:1).-- after "plasmid construct".

On page 36, line 27, insert --; SEQ ID NO:2-- after "(EALA".

*1160
10/23/99*